A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the financings, which included money for a potential challenger to Amgen’s blockbuster Tepezza and a new venture from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio. The analysts also discuss new approaches to drug cancer’s “undruggable” β-catenin pathway, and whether Capricor’s latest regulatory move will give Duchenne muscular dystrophy therapy deramiocel new life at FDA. View full story: https://www.biocentury.com/article/660539 #BiotechFinancing #DrugDevelopment #BetaCatenin #DuchenneMuscularDystrophy #Biopharma 00:00 - Introduction 02:18 - Venture Rounds 12:02 - Drugging β-catenin 18:12 - Capricor &amp; FDA To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

BioCentury This Week

It may be August, but don't tell that to Biotech's company creators. Thirteen venture rounds washed onto the beach last week, bringing in nearly 800 million dollars, a potential challenger to Amgen's blockbuster Tepeza, another cross-border Nuko, and something new from Carty Wunderkind, George Shett.

You're listening to the latest BioCentury This Week podcast. I'm your host, Jeff Cranmer, Executive Editor here at BioCentury. Joined today, as ever, by our Editor-in-Chief, Simone Fishburn, Lauren Martz, Executive Director of Biopharma Intelligence, Senior Biopharma Analyst Danielle Golovan, and Biopharma Analyst Lindsay Martin.

Beyond Venture will discuss five approaches to drug cancer's so-called undruggable beta-catenin pathway, and Capricor, which has had anything but a relaxing day at the beach when it comes to the white water. However, it's encountered at FDA during the McCary era. Will the biotech's latest regulatory move give its DMD therapy new life at the agency?

All right, first up, let's turn to Lindsay, who is most certainly not reporting from the beach. You can tell where I wish I was. I usually spend my beaches at the Jersey Shore, but not so right now. And Lindsay is safely ensconced in Tennessee, far from the jellyfish. Lindsay, we're fond of the term aggressively August here at BioCentury when it comes to biotech news.

It's a term coined by our research director, Meredith Durkin-Wolf, who is really the woman behind the scenes here at BioCentury, keeps everything together and reading smart, filled with great data. So aggressively August, we like these quiet days when all the Europeans are off just hanging out and sipping wine and not working and not giving us news.

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.